N/A
N=23
Treating Phobia With Multivoxel Neuro-reinforcement
Phobia
Bottom Line
View on ClinicalTrials.gov: NCT03655262 ↗Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcome: Primary: Change in Amygdala Reactivity — -.691; -.827; -.278 Beta Coefficient
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Unconscious Neuro-reinforcement (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Jun 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Amygdala Reactivity |
-.691; -.827; -.278 | — |
| PRIMARY Subjective Fear Post-treatment Minus Pre-treatment |
0.32; -0.03; 0.43 | — |
| SECONDARY Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment |
-0.010; -0.097; -0.030 | — |
| SECONDARY Fear Survey Schedule |
-2.46; -5.00; -11.93 | — |
| SECONDARY Stroop Task Post-treatment Minus Pre-treatment |
-0.080; -0.137; -0.030 | — |
Summary
Specific phobias and other anxiety disorders represent a major mental health problem, and present a significant challenge to researchers because effective treatment usually involves repeated exposure to feared stimuli, and the high levels of associated distress can lead to termination of treatment. Recent advances in computational functional magnetic resonance imaging (fMRI) provide a method by which individuals may be unconsciously exposed to fearful stimuli, leading to effective fear reduction while eliminating a primary cause of attrition.
The objective of the current study is to use the novel approach of neuro-reinforcement based on decoded fMRI information to reduce fear responses to fearful stimuli (e.g., spiders, heights) in individuals with phobias, directly and unconsciously in the brain, without repeatedly exposing participants to their feared stimuli.
Participants will be randomized into one of three groups of varying neuro-reinforcement sessions (1, 3, or 5). They will complete tests of subjective fear and directed attention while being scanned by fMRI to measure engagement of amygdala activity to fearful stimuli as well as measured through other indicators of fear such as skin conductance response.
Eligibility Criteria
Inclusion Criteria
- Individual has normal or corrected to normal vision
- Individual has normal or corrected to normal hearing
- Individual is competent to understand informed consent
Exclusion Criteria
- Individual is unable to fill in consent form correctly
- Individual is unable to respond adequately to screening questions
- Individual is unable to maintain focus or to sit during assessment
- Individual has history of: neurological disease or defect (e.g., stroke, traumatic brain injury, schizophrenia or other psychological disorders, or seizures)
- Individual has vision problems (including cataracts, amblyopia, or glaucoma)
- Individual presents with: PTSD, Obsessive Compulsive Disorder, Substance Use Disorder, Current Major Depression, Bipolar Disorder, Psychosis, neurologic diagnoses or unstable serious medical conditions
- Individual does not present with more than one object of specific phobia
- Individual can touch the phobic object category during the pre¬treatment Behavioral Approach Test without presenting significant distress
- Individual is currently prescribed psychotropic medication
Data sourced from ClinicalTrials.gov (NCT03655262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.